# Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

> **NCT04309084** · PHASE1 · UNKNOWN · sponsor: **Celularity Incorporated** · enrollment: 29 (estimated)

## Conditions studied

- Multiple Myeloma
- Neoplasm, Plasma Cell
- Neoplasms by Histologic Type
- Neoplasms
- Hemostatic Disorder
- Vascular Diseases
- Cardiovascular Diseases
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Immune System Diseases
- Antineoplastic Agents
- Analgesics, Non-Narcotic
- Analgesics
- Sensory System Agents
- Peripheral Nervous System Agents
- Physiological Effects of Drugs

## Interventions

- **BIOLOGICAL:** CYNK-001

## Key facts

- **NCT ID:** NCT04309084
- **Lead sponsor:** Celularity Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-12
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-04-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309084, "Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04309084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*